作者
Bing-Xin Zhao,Meng Zhang,Wen-Qian Fu,Xin-Yu Li,Han Meng-lin,Jing Zhang,Wen Gao,Tianhui Guo,Heng-yan Li,Shi-Wen Ai,Haiji Wang,Bi-Yuan Zhang,Qi Wang
摘要
BACKGROUND Neoadjuvant immunochemotherapy (NICT) offers a promising treatment for locally advanced esophageal squamous cell carcinoma (ESCC), yet predicting which patients will achieve a pathological response remains challenging caused by the lack of reliable noninvasive biomarkers. AIM To construct and assess multimodal models integrating radiomics, deep learning (DL), and clinical data to predict NICT response in locally advanced ESCC. METHODS 188 patients who received NICT and radical surgery were enrolled in this retrospective multicenter study. Clinical variables, radiomic features from contrast-enhanced computed tomography, and DL features from three pre-trained architectures (Densenet201, Resnet101, Vgg11) were collected. These features were used to build clinical, radiomics, radiomics-DL, and clinical-radiomics-DL models using four machine learning algorithms. End-to-end DL models were also developed. Model performance was evaluated using area under the curve (AUC), calibration, and decision curve analysis. RESULTS In the external validation cohort, single-modality models (clinical, radiomics, and DL) showed limited predictive performance. The radiomics-DL model constructed with RandomForest (RF) with Vgg11 features achieved the best overall performance, with AUCs of 0.998, 0.855, and 0.779 in the training, internal validation, and external validation cohorts, respectively, and demonstrated good calibration and consistent clinical net benefit. The clinical-radiomics-DL model did not further improve predictive performance. CONCLUSION The radiomics-DL model (Vgg11-RF) predicts NICT response in locally advanced ESCC with promising generalizability, offering a noninvasive tool for individualized treatment decisions.